DRKS00017765已完成2 期
Genotype and phenotype guided supplementation of TAMoxifen standard therapy with ENDOXifen in breast cancer patients - TAMENDOX
Robert Bosch Gesellschaft für medizinische Forschung mbH (RBMF)0 个研究点目标入组 356 人开始时间: 2019年8月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 356
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- Female
入选标准
- •Main Inclusion Criteria: Pre- and postmenopausal female patients with DCIS or stage I, IIA, IIB or IIIA invasive breast cancer who have received at least three months standard tamoxifen treatment before baseline visit.
排除标准
- •Main Exclusion Criteria: Locally advanced (Stadium IIIB or IIIC) or metastatic (Stage IV) breast cancer, ongoing chemotherapy and/or treatment with trastuzumab within the last three months, other active second malignancy, pregnancy, breast feeding/lactation, severe chronic or acute respiratory, cardiac, renal or endocrine diseases.
研究者
相似试验
进行中（未招募）
1 期
Clinical study to investigate the effect of endoxifen therapy in breast cancer patients with reduced endoxifen blood concentration.Patients with ductal carcinoma in situ (DCIS) or early stage breast cancer.MedDRA version: 20.0Level: PTClassification code 10006199Term: Breast cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000418-31-DERobert Bosch Gesellschaft für medizinische Forschung mbH643
已完成
不适用
Analysis of genotypes associated with the treatment effects of Lucentis for age-related macular degeneratioage-related macular degenerationJPRN-UMIN000005584Kyoto University Graduate School of Medicine, Department of Ophthalmology and Visual Sciences600
进行中（未招募）
1 期
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsEUCTR2021-000265-33-NLThe Rotterdam Eye Hospital20
尚未招募
不适用
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsRPE65-associated inherited retinal degenerations (IRDs).NL-OMON22976The Rotterdam Eye Hospital20
招募中
不适用
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsRPE65-associated inherited retinal degenerations10010463NL-OMON50929Oogziekenhuis Rotterdam20